Mona Ashiya

This profile gathers the share dealings of Mona Ashiya across 3 companies, led by Disc Medicine, Inc., Shattuck Labs, Inc. and Sierra Oncology, Inc. We count 12 filings; the first trade dates from 26 January 2022 and the latest from 25 August 2025.

The open-market side counts 4 purchases for €6.9M alongside 5 sales for €16.9M. Taken together, the sales exceed the purchases by €10.0M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 1 share grant and 1 option exercise. So far in 2025, the count stands at 2 purchases and 3 sales.

Half of the purchases are above €1.1M and half below. Clusters matter here: 2 out of 4 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster. Looking at 4 purchases old enough to measure, the stock rose over the following 90 days in 100% of cases; the median change was +64.3%. Past outcomes like these are no guarantee of what comes next.

The newest entry dates from 2 September 2025: an open-market purchase of €3.9M, in Shattuck Labs, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.